RETINA stock news
This page provides real-time market news, earnings updates, and company announcements related to Retina Paints Ltd. (RETINA).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-04-18 02:21 IST
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
Finviz2026-03-16 12:09:48
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
Finviz2026-03-16 12:09:48
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-18 10:12:46
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
Finviz2026-03-18 11:03:58
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
Finviz2026-03-18 11:03:58
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410-Modifier Gene Therapy for Geographic Atrophy
Finviz2026-03-23 11:04:13
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Finviz2026-03-24 11:48:42
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Finviz2026-03-24 12:03:48
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
Finviz2026-03-24 12:18:50
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
Finviz2026-03-25 20:09:40
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda (tarcocimab tedromer) Over Sham
Finviz2026-03-26 10:03:49
Iridex Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-26 20:09:55
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Finviz2026-03-30 20:06:12
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First-in-Class Neuroprotective Candidate for Optic Neuritis
Finviz2026-03-31 08:09:48
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-31 20:48:56
Ocular Therapeutix to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April
Finviz2026-04-01 11:03:12
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
Finviz2026-04-01 11:06:41
EYLEA HD (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
Finviz2026-04-02 16:03:43
ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
Finviz2026-04-07 10:54:52
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA (bevacizumab-vikg) Accepted by FDA
Finviz2026-04-07 12:54:54
Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology
Finviz2026-04-07 20:09:36
Ocular Therapeutix Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD
Finviz2026-04-13 11:03:46
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Finviz2026-04-14 11:03:56
LogiCare3PL Selected as Distribution Partner by Harrow
Finviz2026-04-14 14:33:46
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
Finviz2026-03-18 11:03:58
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410-Modifier Gene Therapy for Geographic Atrophy
Finviz2026-03-23 11:04:13
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Finviz2026-03-24 11:48:42
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Finviz2026-03-24 12:03:48
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
Finviz2026-03-24 12:18:50
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
Finviz2026-03-25 20:09:40
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda (tarcocimab tedromer) Over Sham
Finviz2026-03-26 10:03:49
Iridex Reports Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-26 20:09:55
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Finviz2026-03-30 20:06:12
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First-in-Class Neuroprotective Candidate for Optic Neuritis
Finviz2026-03-31 08:09:48
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Finviz2026-03-31 20:48:56
Ocular Therapeutix to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April
Finviz2026-04-01 11:03:12
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
Finviz2026-04-01 11:06:41
EYLEA HD (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
Finviz2026-04-02 16:03:43
ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
Finviz2026-04-07 10:54:52
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA (bevacizumab-vikg) Accepted by FDA
Finviz2026-04-07 12:54:54
Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology
Finviz2026-04-07 20:09:36
Ocular Therapeutix Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD
Finviz2026-04-13 11:03:46
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Finviz2026-04-14 11:03:56
LogiCare3PL Selected as Distribution Partner by Harrow
Finviz2026-04-14 14:33:46
RETINA stock price change
On the last trading day, RETINA stock closed at 59.39 INR, with a price change of 14.04% for the day.
Trade stock perpsRETINA stock detailsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more